MiMedx Group, Inc $MDXG Shares Acquired by Deutsche Bank AG

Key Points

• Deutsche Bank AG significantly increased its stake in MiMedx Group, boosting its holdings by 144.2% to a total of 321,296 shares, valued at approximately $2.44 million.
• Analysts have raised their ratings on MiMedx Group, with Wall Street Zen upgrading it from "hold" to "strong-buy" and Cantor Fitzgerald increasing the price target from $11 to $12.
• MiMedx Group reported earnings of $0.10 per share, exceeding analysts' expectations, alongside revenue of $98.61 million for the quarter.

Deutsche Bank AG boosted its holdings in MiMedx Group, Inc (NASDAQ:MDXG - Free Report) by 144.2% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 321,296 shares of the company's stock after acquiring an additional 189,750 shares during the period. Deutsche Bank AG owned about 0.22% of MiMedx Group worth $2,442,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of MDXG. Virtus Fund Advisers LLC bought a new position in MiMedx Group in the fourth quarter worth about $35,000. Tower Research Capital LLC TRC lifted its holdings in MiMedx Group by 77.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock worth $63,000 after acquiring an additional 2,837 shares during the last quarter. Legato Capital Management LLC bought a new position in MiMedx Group in the first quarter worth about $101,000. Ameriprise Financial Inc. bought a new position in MiMedx Group in the fourth quarter worth about $115,000. Finally, Sowell Financial Services LLC bought a new position in MiMedx Group in the first quarter worth about $115,000. Institutional investors own 79.15% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on MDXG shares. Wall Street Zen raised MiMedx Group from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 2nd. Cantor Fitzgerald lifted their price target on MiMedx Group from $11.00 to $12.00 and gave the company an "overweight" rating in a report on Thursday, July 31st. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, MiMedx Group has an average rating of "Buy" and an average price target of $12.00.

MiMedx Group Stock Performance

MDXG opened at $7.17 on Thursday. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of 34.14 and a beta of 1.79. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.39 and a quick ratio of 3.90. MiMedx Group, Inc has a 1-year low of $5.47 and a 1-year high of $10.14. The business has a 50 day moving average price of $6.61 and a two-hundred day moving average price of $7.10.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.04. The firm had revenue of $98.61 million during the quarter, compared to the consensus estimate of $90.79 million. MiMedx Group had a return on equity of 23.03% and a net margin of 8.84%. Research analysts predict that MiMedx Group, Inc will post 0.3 EPS for the current fiscal year.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.

Want to see what other hedge funds are holding MDXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiMedx Group, Inc (NASDAQ:MDXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.